Natural selection of tumor variants in the generation of “tumor escape” phenotypes

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.

Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J., Lanier, L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 3,272

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

Inhibition of death receptor signals by cellular FLIP

Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,548

A cell culture model for T lymphocyte clonal anergy

Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance

Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., & Sakaguchi, S. (2002) · Nature Immunology · doi:10.1038/ni759 · Cited by 1,729

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance

Sakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M., & Takahashi, T. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820102.x · Cited by 1,505

Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice

Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465

CD4+CD25+ Immunoregulatory T Cells

McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., & Byrne, M. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00280-7 · Cited by 1,395

Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape

Hahne, M., Rimoldi, D., Schröter, M., Romero, P. J., Schreier, M. H., French, L. E., Schneider, P., Bornand, T., Fontana, A., Liénard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,236

Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives

Kitamura, H., & Tsukamoto, T. (2011) · Cancers · doi:10.3390/cancers3033055 · Cited by 25

Relationship of Dendritic Cell Density, HMGB1 Expression, and Tumor-infiltrating Lymphocytes in Non–Small Cell Lung Carcinomas

Aguilar‐Cázares, D., Meneses-Flores, M., Prado-Garcı́a, H., Islas-Vázquez, L., Rojo-León, V., Romero‐Garcia, S., Rivera-Rosales, R. M., & López-González, J. S. (2013) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3182849808 · Cited by 26

Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity

Russo, V. E. A., Cipponi, A., Raccosta, L., Rainelli, C., Fontana, R., Maggioni, D., Lunghi, F., Mukenge, S., Ciceri, F., Bregni, M., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30605 · Cited by 25

Immunotherapy of melanoma: the good news, the bad ones and what to do next

Marincola, F. M., & Ferrone, S. (2003) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.002 · Cited by 25

Photodynamic Therapy-Generated Cancer Vaccines

Korbelik, M. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-697-9_11 · Cited by 25

Potential therapeutic role of natural killer cells in cancer

Woan, K. V., & Reddy, V. S. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.1.17 · Cited by 24

miR‐2909 regulates ISGylation system via STAT1 signalling through negative regulation of SOCS3 in prostate cancer

Ayub, S. G., & Kaul, D. (2017) · Andrology · doi:10.1111/andr.12374 · Cited by 23

Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients

de Kruijf, E. M., Engels, C. C., van de Water, W., Bastiaannet, E., Smit, V. T. H. B. M., van de Velde, C. J. �., Liefers, G., & Kuppen, P. J. K. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2752-2 · Cited by 24

Cargo from Tumor-Expressed Albumin Inhibits T-Cell Activation and Responses

Graner, M. W., Likhacheva, A., Davis, J., Raymond, A. C., Brandenberger, J., Romanoski, A., Thompson, S., Akporiaye, E. T., & Katsanis, E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1871 · Cited by 26

Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responsesin vitro

Li, G., Zeng, Y., Chen, X., Larmonier, N., Sepassi, M., Graner, M. W., Andreansky, S. S., BREWER, M. A., & Katsanis, E. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03323.x · Cited by 24

Current understanding of the tumor microenvironment of laryngeal dysplasia and progression to invasive cancer

Trivedi, S., Rosen, C. A., & Ferris, R. L. (2016) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0000000000000245 · Cited by 24

Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors

Coosemans, A., Baert, T., Ceusters, J., Busschaert, P., Landolfo, C., Verschuere, T., Rompuy, A. V., Vanderstichele, A., Froyman, W., Neven, P., et al. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000521 · Cited by 24

Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies

Blanco, B., Ramírez-Fernández, Á., & Álvarez‐Vallina, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01792 · Cited by 25

Gene transfer approaches in cancer immunotherapy

Ларин, С. С., Georgiev, G. P., & Киселев, С. Л. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302365 · Cited by 24

Targeting autophagy can synergize the efficacy of immune checkpoint inhibitors against therapeutic resistance: New promising strategy to reinvigorate cancer therapy

Hashemi, M., Khosroshahi, E. M., Tanha, M., Khoushab, S., Bizhanpour, A., Azizi, F., Mohammadzadeh, M., Matinahmadi, A., Koohpar, Z. K., Asadi, S., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37376 · Cited by 25

Targeting Cytotoxic T-Lymphocyte Antigen 4 in Immunotherapies for Melanoma and Other Cancers

Page, D. B., Yuan, J. D., & Wolchok, J. D. (2010) · Immunotherapy · doi:10.2217/imt.10.21 · Cited by 23

miR-221-induced PUMA silencing mediates immune evasion of bladder cancer cells

Fu, B., Wang, Y., Zhang, X., Lang, B., Zhou, X., Xu, X., Zeng, T., Liu, W., Zhang, X., Guo, J., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2837 · Cited by 23

Establishment and characterization of a mouse tumor cell line with irreversible downregulation of MHC class I molecules

Lhotáková, K., Grzelak, A., Poláková, I., Vackova, J., & Šmahel, M. (2019) · Oncology Reports · doi:10.3892/or.2019.7356 · Cited by 23

RB mutation and RAS overexpression induce resistance to NK cell-mediated cytotoxicity in glioma cells

Orozco‐Morales, M., Sánchez‐García, F. J., Cancela, I. G., Hernández‐Pedro, N., Costoya, J. A., de la Cruz, V. P., Moreno‐Jiménez, S., Sotelo, J., & Pineda, B. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0209-x · Cited by 23

A “Big Data” View of the Tumor “Immunome”

Restifo, N. P. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.002 · Cited by 23

Metabolism, LXR/LXR ligands, and tumor immune escape

Russo, V. E. A. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0411198 · Cited by 26

Natural killer cells: can they be useful as adoptive immunotherapy for cancer?

Arai, S., & Klingemann, H.-G. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.2.163 · Cited by 23

Serum IL-17 and IL-6 increased accompany with TGF-β and IL-13 respectively in ulcerative colitis patients.

Feng, J., Yang, Z., Zhu, Y., Liu, Z., Guo, C.-C., & Zheng, X. (2014) · PubMed Central · Cited by 23

Informatics for cancer immunotherapy

Hammerbacher, J., & Snyder, A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx682 · Cited by 23

Vaccines against advanced melanoma

Blanchard, T., Srivastava, P. K., & Duan, F. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2012.08.005 · Cited by 22

Chromosome instability and aneuploidy as context-dependent activators or inhibitors of antitumor immunity

Kuang, X., & Li, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.895961 · Cited by 23

Immunotherapy for Head and Neck Cancer Patients: Shifting the Balance

Turksma, A. W., Braakhuis, B. J. M., Bloemena, E., Meijer, C. J. L. M., Leemans, C. R., & Hooijberg, E. (2012) · Immunotherapy · doi:10.2217/imt.12.135 · Cited by 22

The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review

Johansen, L. L., Lock‐Andersen, J., & Hviid, T. V. F. (2016) · Journal of Immunology Research · doi:10.1155/2016/6829283 · Cited by 22

Perspective: cancer vaccines in the era of immune checkpoint blockade

Cebon, J. S. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9786-z · Cited by 22

Normalization Cancer Immunotherapy for Melanoma

Vesely, M. D., & Chen, L. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.02.005 · Cited by 23

Immunotherapy of MHC Class I-Deficient Tumors

Reiniš, M. (2010) · Future Oncology · doi:10.2217/fon.10.128 · Cited by 22

Evidence for the changes of antitumor immune response during lymph node metastasis in head and neck squamous cell carcinoma

Kumagai, K., Hamada, Y., Gotoh, A., Kobayashi, H., Kawaguchi, K., Horie, A., Yamada, H., Suzuki, S., & Suzuki, R. (2010) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2010.03.030 · Cited by 22

Immunophototherapy Using PDT Combined with Rapid Intratumoral Dendritic Cell Injection

Sur, B. W., Nguyen, P., Sun, C., Tromberg, B. J., & Nelson, E. L. (2008) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2008.00356.x · Cited by 22

Tumor Vaccines

Stevenson, F. K., Rice, J., & Zhu, D. (2004) · Advances in immunology · doi:10.1016/s0065-2776(04)82002-9 · Cited by 22

Pancreas cancer and the role of soluble immunoglobulin-like transcript 3 (ILT3).

Cortesini, R. (2007) · PubMed · Cited by 22

Biomaterials‐Boosted Immunotherapy for Osteosarcoma

Sun, C., Li, S., & Ding, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400864 · Cited by 25

Allogeneic graft‐versus‐hepatoblastoma effect

Inaba, H., Handgretinger, R., Furman, W. L., Hale, G. A., & Leung, W. H. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20404 · Cited by 21

A strategy for enhanced tumor targeting of photodynamic therapy based on Escherichia coli-driven drug delivery system

Dai, T., Ye, F., Hu, P., Pan, X., Chen, J., Huang, Y., Wang, H., Zhang, L., Huang, M., Liu, J., et al. (2020) · Science China Materials · doi:10.1007/s40843-020-1363-2 · Cited by 21

Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma

Engels, C. C., Fontein, D. B. Y., Kuppen, P. J. K., de Kruijf, E. M., Smit, V. T. H. B. M., Nortier, J. W. R., Liefers, G., van de Velde, C. J. �., & Bastiaannet, E. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.338 · Cited by 21

Genetically Targeted T Cells Eradicate Established Breast Cancer in Syngeneic Mice

Wang, H., Wei, H., Zhang, R., Hou, S., Li, B., Qian, W., Zhang, D., Kou, G., Dai, J., & Guo, Y. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2381 · Cited by 21

The role of regulatory T cells in ovarian cancer

Dietl, J., Engel, J. B., & Wischhusen, J. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00861.x · Cited by 21

Regulatory T cells and TGF-β1 in clinically localized renal cell carcinoma: Comparison with age-matched healthy controls

Kim, C., Kim, Y., Kwon, T., Yoon, J. H., Kim, K. H., You, D., Hong, J. H., Ahn, H., & Jeong, I. G. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.11.004 · Cited by 21

Tumor Immunology meets…Immunology: Modified cancer cells as professional APC for priming naïve tumor-specific CD4+ T cells

Eddine, F. B. N., Ramia, E., Tosi, G., Forlani, G., & Accolla, R. S. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356149 · Cited by 21

Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients

Montes, P., Kerick, M., Bernal, M., Hernandez, F. M., Jiménez, P., Garrido, P., Márquez, A., Jurado, M., Martin, J. J., Garrido, F., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26405 · Cited by 21

An Update on Malignant Melanoma Vaccine Research

Ralph, S. J. (2007) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200708030-00001 · Cited by 20

Natural killer cells and cancer therapy, what we know and where we are going

Ghaemdoust, F., Keshavarz‐Fathi, M., & Rezaei, N. (2019) · Immunotherapy · doi:10.2217/imt-2019-0040 · Cited by 20

A therapeutic DC vaccine with maintained immunological activity exhibits robust anti-tumor efficacy

Lu, Y., Shi, Y., Liu, Y., Luo, Z., Zhang, J., Jiang, M., Li, X., Liu, X., Guo, X., Qin, B., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.059 · Cited by 20

Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens.

Kikuchi, E., Yamazaki, K., Nakayama, E., Sato, S., Uenaka, A., Yamada, N., Oizumi, S., Dosaka‐Akita, H., & Nishimura, M. (2008) · PubMed Central · Cited by 20

Anti-angiogenesis immunotherapy

Schoenfeld, J. D., & Dranoff, G. (2011) · Human Vaccines · doi:10.4161/hv.7.9.16407 · Cited by 20

Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens

Wylie, B., Chee, J., Forbes, C. A., Booth, M. W., Stone, S. R., Buzzai, A. C., Abad, A., Foley, B. A., Cruickshank, M. N., & Waithman, J. C. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1609874 · Cited by 20

Prognostic value of HLA class I expression in patients with oral squamous cell carcinoma

Koike, K., Dehari, H., Shimizu, S., Nishiyama, K., Sonoda, T., Ogi, K., Kobayashi, J., Sasaki, T., Sasaya, T., Tsuchihashi, K., et al. (2020) · Cancer Science · doi:10.1111/cas.14388 · Cited by 20

Immunotherapy for older patients with melanoma: From darkness to light?

Iacono, D., Vitale, M. G., Basile, D., Pelizzari, G., Cinausero, M., Poletto, E., Pascoletti, G., & Minisini, A. M. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12917 · Cited by 20

Combination antibody‐based cancer immunotherapy

Takeda, K., Okumura, K., & Smyth, M. J. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00529.x · Cited by 20

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates

Seyhan, A. A., & Carini, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010041 · Cited by 22

Allogeneic MHC Gene Transfer Enhances an Effective Antitumor Immunity in the Early Period of Autologous Hematopoietic Stem Cell Transplantation

Kobayashi, A., Hara, H., Ohashi, M., Nishimoto, T., Yoshida, K., Ohkohchi, N., Yoshida, T., & Aoki, K. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1163 · Cited by 19

Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro

Saito, H., Kitagawa, K., Yoneda, T., Fukui, Y., Fujsawa, M., Bautista, D., & Shirakawa, T. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.21 · Cited by 19

NLRC5: new cancer buster?

Tang, F. R., Xu, Y., & Zhao, B. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05253-5 · Cited by 19

Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade

Hübbe, M. L., Jæhger, D. E., Andresen, T. L., & Andersen, M. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.578349 · Cited by 20

CAR-T Cells Targeting Immune Checkpoint Pathway Players

Golubovskaya, V. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2704121 · Cited by 19

Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study

Zhang, Y., Song, L., Zeng, L., Xiong, Y., Liu, L., Zhou, C., Yang, H., Wang, Z., Xia, Q., Jiang, W., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10045-0 · Cited by 19

Programmed death 1: a critical regulator of T-cell function and a strong target for immunotherapies for chronic viral infections

Trautmann, L., Said, E. A., Halwani, R., Janbazian, L., Chomont, N., Far, M. E., Breton, G., Haddad, E. K., & Sékaly, R. (2007) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3280ebb5c9 · Cited by 19

Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells

Bergot, A., Durgeau, A., Levacher, B., Colombo, B. M., Cohen, J. L., & Klatzmann, D. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.21 · Cited by 19

Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer

Honma, I., Torigoe, T., Hirohashi, Y., Kitamura, H., Sato, E., Masumori, N., Tamura, Y., Tsukamoto, T., & Sato, N. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-103 · Cited by 19

Late pulmonary metastases of renal cell carcinoma immediately after post-transplantation immunosuppressive treatment: a case report

Cózar, J. M., Aptsiauri, N., Tallada, M., Garrido, F., & Ruiz‐Cabello, F. (2008) · Journal of Medical Case Reports · doi:10.1186/1752-1947-2-111 · Cited by 19

Immune modulation by dendritic-cell-based cancer vaccines

Kumar, C., Kohli, S., Bapsy, P. P., Vaid, A. K., Jain, M. M., Attili, V. S. S., & Sharan, B. (2017) · Journal of Biosciences · doi:10.1007/s12038-017-9665-x · Cited by 19

γδ T-cell immunotherapy for lung cancer

Yoshida, Y., Nakajima, J., Wada, H., & Kakimi, K. (2011) · Surgery Today · doi:10.1007/s00595-010-4478-7 · Cited by 18

Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability

Spear, T. T., Riley, T. P., Lyons, G. E., Callender, G. G., Roszkowski, J. J., Wang, Y., Simms, P. E., Scurti, G. M., Foley, K. C., Murray, D. C., et al. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.2a1215-561r · Cited by 18

Radiotherapy suppressed tumor-specific recruitment of regulator T cells via up-regulating microR-545 in Lewis lung carcinoma cells.

Chen, L., Xiao, W. L., Zhu, N., Liu, Z., Yang, J., Wang, Y., & Hong, M. (2015) · PubMed Central · Cited by 18

HLA‐G, HLA‐E, and IDO overexpression predicts a worse survival of Tunisian patients with vulvar squamous cell carcinoma

Boujelbène, N., Yahia, H. B., Babay, W., Gadria, S., Zemni, I., Azaiez, H., Dhouioui, S., Zidi, N., Mchiri, R., Mrad, K., et al. (2019) · HLA · doi:10.1111/tan.13536 · Cited by 18

Decreased Tumor Surveillance after Adoptive T-Cell Therapy

Matter, M. S., Pavelic, V., Pinschewer, D. D., Mumprecht, S., Eschli, B., Giroglou, T., von Laer, D., & Ochsenbein, A. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4372 · Cited by 18

Dendritic cell immunotherapy for breast cancer

Pinzón‐Charry, A., Schmidt, C., & López, J. A. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.6.591 · Cited by 18

Mouse models of efficient and inefficient anti-tumor immunity, with emphasis on minimal residual disease and tumor escape

Egorov, I. K. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0007-8 · Cited by 18

Immunobiology of the human MHC class I chain-related gene A (MICA): from transplantation immunology to tumor immune escape

Zwirner, N. W., Fuertes, M. B., Girart, M. V., Domaica, C. I., & Rossi, L. E. (2006) · Cited by 18

Cellular Therapies in Acute Lymphoblastic Leukemia

Park, J. H., Sauter, C. S., & Brentjens, R. J. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.015 · Cited by 17

An ecosystem framework for understanding and treating disease

Hochberg, M. (2018) · Evolution Medicine and Public Health · doi:10.1093/emph/eoy032 · Cited by 16

Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy

Silva, S. B., Wanderley, C. W. S., & Colli, L. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.826577 · Cited by 17

Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer

Navarro-Ocón, A., Blaya-Cánovas, J. L., López-Tejada, A., Blancas, I., Sanchez-Martin, R. M., Garrido, M. J., Griñán‐Lisón, C., Calahorra, J., Cara, F. E., Ruiz‐Cabello, F., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030505 · Cited by 17

Chromosomal Instability as Enabling Feature and Central Hallmark of Breast Cancer

Castellanos, G., Valbuena, D. S., Pérez, E., Villegas, V. E., & Rondón‐Lagos, M. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s383759 · Cited by 22

Immunotherapy in leukaemia

Mu, X., Chen, C., Dong, L., Kang, Z., Sun, Z., Chen, X., Zheng, J., & Zhang, Y. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023101 · Cited by 18

The complex role of IL-10 in malignant ascites: a review

Huang, Y. M., Zou, K., Jiang, H., & Li, Z. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03616-y · Cited by 17

Human IL18-IL2 fusion protein as a potential antitumor reagent by enhancing NK cell cytotoxicity and IFN-γ production

Du, G., Ye, L., Zhang, G., Dong, Q., Liu, K., & Tian, J. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1248-5 · Cited by 17

Xenovaccinotherapy for colorectal cancer

Seledtsov, V. I., Niza, N. A., Fel’de, M. A., Shishkov, A. A., Самарин, Д. М., Seledtsova, G. V., & Seledtsov, D. V. (2007) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.09.016 · Cited by 17

Recurrent hepatocellular carcinoma cells with stem cell-like properties: possible targets for immunotherapy

Xu, X., Xing, B., Meihao, H., Xu, Z.-L., Xie, Y., Dai, G., Gu, J., Wang, Y., & Zhang, Z. (2009) · Cytotherapy · doi:10.3109/14653240903390803 · Cited by 17

Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice

Kavunja, H. W., Lang, S., Sungsuwan, S., Yin, Z., & Huang, X. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1948-9 · Cited by 17

Advances in immunotherapy for pediatric acute myeloid leukemia

Bonifant, C. L., Velasquez, M. P., & Gottschalk, S. M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1384463 · Cited by 17

Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling

Kolben, T., Jeschke, U., Reimer, T., Karsten, N., Schmoeckel, E., Semmlinger, A., Mahner, S., Harbeck, N., & Kolben, T. M. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2551-y · Cited by 16

The microRNA target site landscape is a novel molecular feature associating alternative polyadenylation with immune evasion activity in breast cancer

Kim, S., Bai, Y., Fan, Z., Diergaarde, B. B., Tseng, G. C., & Park, H. J. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa191 · Cited by 19

Unveiling the Hidden Treasury: CIITA-Driven MHC Class II Expression in Tumor Cells to Dig up the Relevant Repertoire of Tumor Antigens for Optimal Stimulation of Tumor Specific CD4+ T Helper Cells

Forlani, G., Shallak, M., Celesti, F., & Accolla, R. S. (2020) · Cancers · doi:10.3390/cancers12113181 · Cited by 17

Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics

Yan, Y., Gao, R., Trinh, T. L. P., & Grant, M. B. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0250 · Cited by 17

Rapid Assessment of Recognition Efficiency and Functional Capacity of Antigen-Specific T-Cell Responses

Kohrt, H. E. K., Shu, C.-T., Stuge, T. B., Holmes, S., Weber, J. S., & Lee, P. P. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000162780.96310.e4 · Cited by 17

Detection of Spontaneous CD4+ T-Cell Responses in Melanoma Patients against a Tyrosinase-Related Protein-2–Derived Epitope Identified in HLA-DRB1*0301 Transgenic Mice

Paschen, A., Song, M., Osen, W., Nguyen, X. D., Mueller-Berghaus, J., Fink, D., Daniel, N., Donzeau, M., Nagel, W., Kropshofer, H., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0170 · Cited by 17

Over-expressed IgG2 antibodies against O-acetylated sialoglycoconjugates incapable of proper effector functioning in childhood acute lymphoblastic leukemia

Bandyopadhyay, S. (2004) · International Immunology · doi:10.1093/intimm/dxh198 · Cited by 17

Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy

Elkord, E., Hawkins, R. E., & Stern, P. L. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.4.385 · Cited by 17

Do autochthonous tumors interfere with effector T cell responses?

Blankenstein, T. J. F. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.007 · Cited by 21

A novel microenvironment regulated system CAR-T (MRS.CAR-T) for immunotherapeutic treatment of esophageal squamous carcinoma

Wang, L., Wang, X., Wu, Y., Wang, J., Zhou, W., Wang, J., Guo, H., Zhang, N., Zhang, L., Hu, X., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216303 · Cited by 16

Toward general prophylactic cancer vaccination

Hobohm, U. (2009) · BioEssays · doi:10.1002/bies.200900025 · Cited by 16

Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes

Akazawa, Y., Nobuoka, D., Takahashi, M., Yoshikawa, T., Shimomura, M., Mizuno, S., Fujiwara, T., Nakamoto, Y., & Nakatsura, T. (2019) · Cancer Science · doi:10.1111/cas.14022 · Cited by 16

Regresión completa de nevos melanocíticos: correlación clínica, dermatoscópica e histológica de una serie de 13 casos

Martín, J. M., Rubio, M., Bella, R., Jordá, E., & Monteagudo, C. C. (2012) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2011.11.004 · Cited by 16

Antitumor activity of chimeric immunoreceptor gene‐modified Tc1 and Th1 cells against autologous carcinoembryonic antigen‐expressing colon cancer cells

Sasaki, T., Ikeda, H., Satō, M., Ohkuri, T., Abé, H., Kuroki, M., Onodera, M., Miyamoto, M., Kondo, S., & Nishimura, T. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00271.x · Cited by 15

Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells

Tanida, T., Tanemura, M., Miyoshi, E., Nagano, H., Furukawa, K., NONAKA, Y., Akita, H., Hama, N., Wada, H., Kawamoto, K., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2717 · Cited by 16

Michor F: A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability

Iwami, S., Haeno, H., & Franziska Michor, A. (2016)

A Race between Tumor Immunoescape and Genome Maintenance Selects for Optimum Levels of (epi)genetic Instability

Iwami, S., Haeno, H., & Michor, F. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002370 · Cited by 14

Immunotherapy and immunoselection ? tumour escape as the final hurdle

Pawelec, G. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.02.091 · Cited by 30

Strategies for tumor immune escape

Piemonti, L., Zerbi, A., & Carlo, V. D. (2003) · Drugs of today · doi:10.1358/dot.2003.39.9.799478 · Cited by 8

Abstract 4034: Immunotherapy generates selective pressure to create an escape tumor with increased susceptibility to treatment with T cell based therapies

Pan, J. H., Vodnala, S. K., Eil, R. L., Yu, Z., Gartner, J. J., Clever, D. C., Roychoudhuri, R., Patel, S. J., Klebanoff, C. A., Sukumar, M., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4034